| Property | Value |
|----------|-------|
| Category | Neuroinflammation Biomarker |
| Target | C3 protein, C3a, C3b, C3c, C3d fragments |
| Sample Type | CSF, Plasma, Serum |
| Diseases | AD, ALS, MS, PD, FTD |
| Sensitivity | Moderate |
| Specificity | Low-Moderate |
Complement C3 is the most abundant complement protein in human serum, with concentrations ranging from 1.2 to 1.5 g/L[@merle2015]. The C3 gene is located on chromosome 19p13.3 and encodes a 1,627 amino acid polypeptide that undergoes extensive post-translational modification[@wu2016]. In the central nervous system (CNS), C3 is synthesized by astrocytes, microglia, and even neurons under pathological conditions, creating a localized complement production system independent of peripheral sources[@mcgeer2015].
C3 functions as the convergence point for all complement activation pathways. Upon activation, C3 is cleaved by C3 convertases (C4b2a in classical/lectin pathways; C3bBb in alternative pathway) into two critical fragments: C3a, a potent anaphylatoxin that promotes inflammation, and C3b, an opsonin that marks targets for phagocytosis[@merle2015]. Further cleavage of C3b produces C3c and C3d, the latter serving as a stable marker of prior complement activation that persists in tissues and can be detected diagnostically[@ricklin2010].
The C3a receptor (C3aR) is expressed on neurons, astrocytes, and microglia, enabling direct signaling effects of C3a in the brain[@benoit2013]. The C3a-C3aR axis promotes microglial activation, cytokine release, and inflammatory cell recruitment, making it a therapeutic target for neuroinflammation[@benoit2013].
Accurate measurement of C3 and its fragments requires sensitive and specific analytical approaches:
Elevated CSF C3 levels have been documented in early-stage AD, with studies showing significant increases compared to cognitively normal controls[@zhou2020]. Importantly, C3 and its fragments co-localize with amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs), indicating local complement activation at sites of pathology[@mcgeer2015]. The complement system participates in Aβ-induced synaptic loss through C1q and C3-dependent mechanisms, where C1q tags synapses for elimination by microglia expressing C3 receptors[@stevens2007].
Genome-wide association studies (GWAS) have identified complement receptor 1 (CR1) and complement component 4 (C4) as genetic risk loci for AD, further implicating the complement system in disease pathogenesis[@lambert2015]. The age-related increase in C1q and C3 in the brain may contribute to heightened synaptic vulnerability in aging and AD[@stephan2013].
Multiple studies have reported elevated CSF and plasma C3 levels in ALS patients, with correlations to disease progression rate and severity[@vessie2021]. Complement activation appears to contribute to motor neuron degeneration through several mechanisms: direct membrane attack complex (MAC) deposition on motor neurons, microglial activation driven by C3a-C3aR signaling, and astrocyte-mediated complement production[@vessie2021].
Animal models of ALS show that complement inhibition can reduce microglial activation and slow disease progression, highlighting the therapeutic potential of targeting C3[@liddelow2019]. The C5-C5aR1 axis has also been implicated, with clinical trials evaluating eculizumab (a C5 inhibitor) in ALS[@liddelow2019].
CSF C3 levels are elevated in relapsing-remitting MS and correlate with disease activity as assessed by MRI findings[@lee2020]. Complement activation contributes to demyelination and oligodendrocyte death through formation of the membrane attack complex on myelin sheaths and oligodendrocytes[@lee2020]. The alternative pathway appears particularly important in MS pathogenesis, with Factor B and Factor D showing increased activity[@lee2020].
Complement component C3a promotes inflammatory cell recruitment across the blood-brain barrier (BBB), while C3b opsonizes myelin for phagocytic removal by microglia and macrophages[@lee2020]. Therapeutic strategies targeting complement, including the C1 inhibitor eculizumab and the C3 inhibitor pegcetacoplan, are under investigation in MS[@ricklin2013].
PD patients demonstrate elevated C3 levels in both CSF and blood, with correlations to disease severity measured by Unified Parkinson's Disease Rating Scale (UPDRS) scores[@wang2021]. Microglial complement production contributes to chronic neuroinflammation and progressive dopaminergic neuron loss in the substantia nigra[@wang2021].
The complement system may also interact with alpha-synuclein pathology, as C1q and C3 can bind to alpha-synuclein aggregates, potentially promoting inflammatory responses[@fuller2020]. This suggests that complement biomarkers may reflect the burden of synucleinopathy in PD.
In AD, the complement system transitions from a protective developmental pruning mechanism to a pathological driver of synaptic loss. Aβ plaques activate the classical complement pathway through C1q binding, initiating a cascade that ultimately generates C3[@mcgeer2015]. C1q "tags" synapses near plaques for elimination, and C3b marks them for microglial phagocytosis via complement receptors CR3 and CR4[@stevens2007]. This excessive synaptic pruning correlates strongly with cognitive decline and may precede overt plaque deposition[@stevens2007].
Microglia, particularly disease-associated microglia (DAM) or TREM2-associated microglia, upregulate complement proteins including C1q and C3 in response to Aβ[@wang2020]. The TREM2-C3 axis represents a critical pathway linking microglial activation to complement-mediated neurotoxicity[@wang2020].
Motor neuron injury triggers complement activation through damage-associated molecular patterns (DAMPs) released from dying neurons[@vessie2021]. Astrocytes and microglia in the spinal cord produce C3 in response to inflammation, creating a localized toxic environment[@vessie2021]. MAC deposition has been observed in motor nuclei of ALS patients and animal models, directly contributing to motor neuron death[@liddelow2019].
The C5a-C5aR1 signaling axis promotes microglial activation and has been targeted in preclinical ALS models with beneficial effects[@liddelow2019]. Inhibition of complement using systemically administered inhibitors can reduce microglial activation and extend survival in SOD1 mouse models of ALS[@liddelow2019].
In MS, myelin antigens form immune complexes that activate the classical complement pathway, generating C3 and MAC[@lee2020]. Oligodendrocytes are particularly vulnerable to complement-mediated killing due to their limited regenerative capacity[@lee2020]. The complement regulatory proteins CD55 and CD59 are downregulated in MS lesions, exacerbating complement-mediated damage[@lee2020].
Microglial C3 expression is upregulated in active MS lesions, and C3a promotes recruitment of peripheral immune cells across the BBB[@ricklin2013]. The balance between complement activation and regulation determines the extent of demyelination and axonal injury.
The centrality of C3 in complement-mediated neuroinflammation makes it an attractive therapeutic target:
Despite its promise as a biomarker, C3 measurement has several limitations:
The study of Complement Component 3 (C3) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.